Zimmer Biomet Holdings, Inc. (ZBH)
NYSE: ZBH · Real-Time Price · USD
90.62
-1.03 (-1.12%)
At close: Aug 1, 2025, 4:00 PM
91.00
+0.38 (0.42%)
After-hours: Aug 1, 2025, 7:57 PM EDT
Aspen Technology Revenue
Zimmer Biomet Holdings had revenue of $1.91B in the quarter ending March 31, 2025, with 1.05% growth. This brings the company's revenue in the last twelve months to $7.70B, up 3.30% year-over-year. In the year 2024, Zimmer Biomet Holdings had annual revenue of $7.68B with 3.85% growth.
Revenue (ttm)
$7.70B
Revenue Growth
+3.30%
P/S Ratio
2.37
Revenue / Employee
$452,853
Employees
17,000
Market Cap
17.93B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.68B | 284.40M | 3.85% |
Dec 31, 2023 | 7.39B | 454.30M | 6.55% |
Dec 31, 2022 | 6.94B | 112.60M | 1.65% |
Dec 31, 2021 | 6.83B | 699.80M | 11.42% |
Dec 31, 2020 | 6.13B | -1.85B | -23.24% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 57.37B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ZBH News
- 11 days ago - Zimmer Biomet Q2 Preview: Combining Monogram Autonomous Robotics With ROSA - Seeking Alpha
- 16 days ago - MONOGRAM TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Monogram Technologies Inc. - MGRM - Business Wire
- 23 days ago - Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2025 Financial Results - PRNewsWire
- 2 months ago - Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2025 - PRNewsWire
- 2 months ago - Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas - PRNewsWire
- 2 months ago - Zimmer Biomet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - PRNewsWire
- 3 months ago - These Analysts Lower Their Forecasts On Zimmer Biomet After Q1 Results - Benzinga
- 3 months ago - Zimmer Biomet: Stronger Cash Flows Needed Before The Stock Rebounds - Seeking Alpha